














































The inter-species hormesis, or xenohormesis, 
hypothesis originally proposed by Dr. David A. Sinclair 
[1, 2] states that stress-induced synthesis of plant 
polyphenols and many other phytochemicals provides 
an environmental chemical signature that upregulates 
stress resistance pathways in plant consumers, including  
 
 













































humans [1-5]. The existence of xenohormesis might 
explain how chemical compounds produced by plants 
and other autotrophs to defend against adverse 
environmental conditions can generate beneficial effects 
in the heterotrophs (animals and fungi) that consume 
them. Thus, we can take advantage of the healthy 
benefits that are chemically encrypted within plant-
derived biocompounds. The natural polyphenolic 


























Abstract: Aging  is  associated  with  common  conditions,  including  cancer,  diabetes,  cardiovascular  disease,  and
Alzheimer’s disease. The  type of multi‐targeted pharmacological approach necessary  to address a complex multifaceted
disease  such  as  aging  might  take  advantage  of  pleiotropic  natural  polyphenols  affecting  a  wide  variety  of  biological
processes. We have recently postulated that the secoiridoids oleuropein aglycone (OA) and decarboxymethyl oleuropein
aglycone  (DOA),  two complex polyphenols present  in health‐promoting extra virgin olive oil  (EVOO), might constitute a
new  family of plant‐produced gerosuppressant agents. This paper describes an analysis of the biological activity spectra
(BAS) of OA and DOA using PASS (Prediction of Activity Spectra for Substances) software. PASS can predict thousands of
biological  activities,  as  the  BAS  of  a  compound  is  an  intrinsic  property  that  is  largely  dependent  on  the  compound’s
structure and reflects pharmacological effects, physiological and biochemical mechanisms of action, and specific toxicities.
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compound resveratrol (3,5,4’-trihydroxystilbene) has 
emerged as an archetypal xenohormetic mediator of 
longevity that clearly delays or attenuates many age-
related chronic diseases in animal models [6-12].  
 
Dr. Mikhail V. Blagosklonny has recently proposed that 
“hormesis does not make sense except in the light of 
TOR-driven aging” [6]. In this scenario, aging-related 
disease (e.g., atherosclerosis, diabetes, cancer, and other 
diseases) can be understood as the product of 
synergistic interactions between our evolutionary path 
to sedentarism, which increases a number of gero-
promoting factors (e.g., nutrients, growth factors, 
cytokines, insulin) that upregulate key gerogenes (e.g., 
the nutrient-sensing mammalian target of rapamycin 
[mTOR]), and the “defective design” of central energy 
metabolism sensors that function either as metabolic 
gerogenes (e.g., mTOR) or metabolic gerosuppressors 
(e.g., AMP-activated protein kinase [AMPK], which 
antagonizes the gerogenic activity of mTOR) [13-29]. 
This “defective design” refers to (a) the ability of 
metabolic gerogenes to continue, in an aimless but 
harmful manner, a developmental program that was 
beneficial early in life but was not switched off upon its 
completion and therefore drives aging; and (b) the 
weakness of the metabolic gerosuppressors that 
antagonize the metabolo-gerogenic pathway. In this 
metabolic framework for aging-related diseases, 
upregulation of metabolic gerogenes limits lifespan by 
accelerating age-related diseases, whereas the 
responsiveness of metabolo-gerosuppressor signaling 
should decline with aging because robust and 
continuous activation of metabolic suppressors in 
response to metabolic stresses results in accelerated 
aging [30, 31]. In other words, the ability of metabolic 
gerogenes to drive aging can be triggered or accelerated 
by the loss of responsiveness of critical metabolic 
gerosuppressors to their appropriate activation.  
 
If the upregulation of metabolic gerogenes limits 
lifespan by accelerating the progression of age-related 
diseases, such as atherosclerosis or cancer, the 
behavioral and/or pharmacological suppression of 
metabolic gerogene-driven aging (e.g., via non-
permanent activation of metabolic gerosuppressors) 
should increase healthy lifespan. We have recently 
explored, for the first time, the putative AMPK/mTOR-
related xenohormetic nature of complex polyphenols 
that are naturally present in extra virgin olive oil 
(EVOO), a pivotal component of the Mediterranean-
style diet that has been repeatedly associated with a 
reduction in age-related morbidity and a longer life 
expectancy [29]. Using a crude EVOO phenolic extract 
that is highly enriched in the secoiridoids oleuropein 
aglycone (OA) and decarboxymethyl oleuropein 
aglycone (DOA), we have shown that EVOO 
oleuropeins, which provide an effective defense against 
the attack of plants by herbivores and pathogens, are 
bona fide xenohormetins that are able to activate the 
gerosuppressor AMPK and trigger numerous 
resveratrol-like anti-aging transcriptomic signatures in 
biologically aggressive cancer cells. As such, we 
postulated that EVOO secoiridoids constitute a new 
family of plant-produced gerosuppressant agents that 
molecularly “repair” the aimless (and harmful) 
AMPK/mTOR-driven quasi-program that leads to aging 
and aging-related diseases, including cancer [29, 32].  
 
As a compound’s biological activity spectrum (BAS) is 
an intrinsic property that is representative of different 
pharmacological effects, physiological and biochemical 
mechanisms of action, and specific toxicities, and the 
BAS is largely dependent on the structural nature of a 
compound [33-43], we recently hypothesized that 
computerized prediction of BAS might help us to 
elucidate hypothesis-generating pharmacological effects, 
mechanisms of action, and targets underlying the anti-
aging/anti-cancer activity of gerosuppressant oleuropeins 
present in EVOO. Here, we employed Prediction of 
Activity Spectra for Substances (PASS) software [33-43] 
(www.pharmaexpert.ru/passonline/index.php), which is 
hosted by the V. N. Orechovich Institute of Biomedical 
Chemistry (www.ibmc.msk.ru/en) under the aegis of the 
Russian Foundation of Basic Research. Using 
Pharmaexpert (www.genexplain.com/ pharmaexpert), a 
tool developed to analyze the BAS of substances 
predicted by PASS, we characterized EVOO 
oleuropeins with different types of biological activities 
based on multiple mechanisms of action, analyses of 
activity-activity relationships, and drug-drug 
interactions. We now report on how a multi-targeted 
pharmacological approach needed for a complex 
multifaceted disease, such as aging, might take 
advantage of EVOO-derived polyphenols, 





Description of the chemical structures of EVOO 
oleuropeins 
 
 OA and DOA are structurally related secoiridoids with 
identical dihydroxylated aromatic moieties that differ 
only due to the presence of a methoxycarbonyl group on 
C-5 of the dihydropyrane ring of OA (Fig. 1). As the 
PASS tool interprets the BAS based on the 2D structure 
of molecules, the hemiacetalic (“cyclic”) and 
dialdehidic (“open”) structures of OA and DOA were 
drawn using ACD/ChemSketch version 12, then saved  
  






















as MDL Molfiles (*.mol) and directly uploaded into the 
PASS prediction program to predict the biologically 
active spectra of the molecules.  
 
PASS estimation of the BAS of EVOO oleuropeins 
 
Predictions were made using the PASS12 refined version 
of the program (www.genexplain.com/pass), which 
predicts 1,105 types of biological activities with a mean 
prediction accuracy in leave-one-out cross-validation 
(LOOCV) of 96%. PASS prediction tools are constructed 
using principal compounds from the MDDR database 
(produced by Accelrys and Prous Science), which is 
continuously updated with biologically relevant 
compounds. The PASS training set consisted of 287,633 
known biologically active substances (e.g., drugs, drug-
candidates, lead compounds, toxic compounds) compiled 
from various sources, including publications, patents, 
chemical databases, and “gray” literature [33-43].  
 
Figs. 2 and 3 show only the activities predicted at a Pa 
(probability “to be active”) > 0.200 for the hemiacetalic 
and dialdehidic forms of OA (Fig. 2) and DOA (Fig. 3), 
grouped using PharmaExpert (www.genexplain.com/ 
pharmaexpert), a tool that was developed to analyze the 
biological activity spectra of substances predicted by 
PASS. PharmaExpert software analyzes the 
relationships between biological activities 
(“mechanism-effect(s)” and “effect-mechanism(s)”), 
identifies probable drug-drug interactions, and searches 
for compounds acting on multiple targets [33-43].  
 
Different types of biological activities are divided into 






















effects, metabolism-related actions, transporter terms, 
gene expression terms, and toxic/adverse effects. 
 
The mechanisms of action reflect the interactions of 
biologically active compounds with biological entities 
at the macromolecular level. In addition to the expected 
antioxidant mechanism of action of OA (Pa = 0.872), 
PASS predicts some new mechanisms for the cyclic 
hemiacetalic form of OA, including cardiotonic (Pa = 
0.826), immunomodulator (Pa = 0.598), vasodilator (Pa 
= 0.487), and hepatoprotectant (Pa = 0.453) activities. 
The cyclic hemiacetalic form of DOA is similarly 
predicted to exhibit an expected antioxidant mechanism 
of action (Pa = 0.790) while lacking all of the 
cardiotonic, immunomodulator, and hepatoprotectant 
mechanisms predicted for the cyclic hemiacetalic form 
of OA.  
 
The open dialdehydic form of OA is predicted to lack 
all of the cardiotonic, immunomodulator, and 
hepatoprotectant mechanisms of action suggested for 
the cyclic hemiacetalic form of OA. Moreover, the 
expected antioxidant mechanism of OA is notably 
reduced when PASS predictions are used to estimate the 
probable mechanisms of action of the open dialdehydic 
form of OA (Pa = 0.247). The top predicted mechanism 
of action for the open dialdehydic form of OA is GABA 
aminotransferase inhibitor activity (Pa = 0.433). The 
open dialdehydic form of DOA is predicted to lack (Pa 
= 0.221) the highly predicted antioxidant mechanism of 
action of the cyclic hemiacetalic form of DOA, while 
gaining new mechanisms such as acting as a tyrosine 3  
hydroxylase inhibitor (Pa = 0.407) and cholesterol 










































































































































The pharmacological effects reflect the 
pharmacological action or pharmacotherapeutic 
application of the compound. Some of the most likely 
anti-aging/anti-cancer pharmacological effects, showing 
higher Pa values in the predictions for the cyclic 
hemiacetalic form of OA, include anti-antioxidant (Pa = 
0.872), anti-inflammatory (Pa = 0.809), anti-neoplastic 
(Pa = 0.610), apoptosis agonist (Pa = 0.419), and 
chemopreventive (Pa = 0.387) effects. The cyclic 
hemiacetalic form of DOA conserves all the anti-
aging/anti-cancer pharmacological effects observed in 
the prediction for the cyclic hemiacetalic form OA, but 
displaying somewhat lower Pa values (i.e., anti-oxidant 
[Pa = 0.790], anti-inflammatory [Pa = 0.693], and anti-
neoplastic [Pa = 0.637] effects). The sole exception is 
the apoptosis agonist effect, which is predicted to occur 
with a higher probability (Pa = 0.610) for the cyclic 
hemiacetalic form of DOA.  
 
Remarkably, the open dialdehydic form of OA 
exclusively conserves the chemopreventive effect of the 
cyclic hemiacetalic form of OA, and with an even 
higher Pa value (0.596). Similarly, the open dialdehydic 
form of DOA notably gains a strong anti-aging/anti-
cancer-related chemopreventive effect (Pa = 0.766) 
compared with the weaker effect observed in the 
activity prediction for the cyclic hemiacetalic form of 
DOA (Pa = 0.372).  
 
The metabolism-related actions reflect interactions of 
chemical compounds with metabolic enzymes. The 
cyclic hemiacetalic forms of OA and DOA are predicted 
to function as CYP1A2 inhibitors (Pa = 0.605 and Pa = 
0.451, respectively).  
 
The open dialdehydic form of OA is predicted to function 
as a substrate of GST A and GST P1-1 (Pa = 0.633 and 
0.430, respectively). Similarly, the open dialdehydic form 

















1 substrate (Pa = 0.579 and 0.400, respectively).  
 
The transporter terms reflect the interaction of chemical 
compounds with transporters (e.g., P-glycoprotein 
substrate, P-glycoprotein inhibitor, P-glycoprotein 
inducer). The cyclic and open forms of OA as well as 
the cyclic form of DOA are all predicted to function as 
P-glycoprotein substrates, but with a low Pa (∼0.220); 
this activity is not predicted for the open dialdehydic 
form of DOA.  
 
The gene expression terms reflect the influence of 
chemical compounds on the expression of certain genes. 
The cyclic hemiacetalic form of OA is predicted to 
negatively regulate ICAM1 gene expression with a low 
Pa (0.228). The cyclic hemiacetalic form of DOA is 
similarly predicted to inhibit the expression of ICAM1 
(Pa = 0.329) and AR (Pa = 0.235) genes.   
 
In addition to inhibiting the expression of the ICAM1 
gene (Pa = 0.303) and AR (Pa = 0.290), as indicated for 
the cyclic hemiacetalic form of OA, the open 
dialdehydic form is predicted to inhibit the expression 
of the TNF (Pa = 0.392) and NOS2 (Pa = 0.253) genes. 
The open dialdehydic form of DOA, in addition to 
inhibiting the ICAM1 (Pa = 0.295) and AR (Pa = 0.310) 
genes, as indicated for its cyclic hemiacetalic form, is 
also predicted to inhibit the expression of the TNF (Pa = 
0.331) and NOS2 (Pa = 0.208) genes.    
 
The toxic/adverse effects reflect the specific toxicities or 
adverse reactions of the chemical compounds. No 
highly predicted toxic/adverse effects are indicated for 
the cyclic hemiacetalic form of OA beyond ulceration 
(Pa = 0.215). Interestingly, other indirectly related anti-
aging/anti-cancer pharmacological effects with low Pa 
values are predicted for the cyclic hemiacetalic form of 
DOA, specifically embryotoxic (Pa = 0.260) and 
teratogen (Pa = 0.248) effects.  




set  is very  low but about 90% of active compounds will be missed).  If one  lowers  the Pa  threshold  to 0.8,  the probability  to  find
inactive compounds is still low, but about 80% of active compounds will be missed, etc. Another important aspect of PASS predictions
is  the  compounds’ novelty.  If one  limits  to high Pa  values, one may  find  close analogues of known biologically active  substances
among the tested compounds. For instance, for Pa > 0.7, the chance to experimentally find the biological activity is high, but some of
the activities may be close analogue of known pharmaceutical agents.  If one chooses 0.5<Pa<0.7 values,  the chances of obtaining
activity  in  the  experiment  are  lower,  but  the  compound may be  less  similar  to  known  pharmaceutical  agents.  For  Pa  <  0.5,  the
chances of obtaining activity  in  the experiment are even  lower, but  if activity  is  found,  the compound might happen  to be a new
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The open dialdehydic form of OA, in addition to 
showing skin irritation (Pa = 0.971) and eye irritation 
(Pa = 0.774) effects, is predicted to exhibit embryotoxic 
(Pa = 0.457) and teratogenic (Pa = 0.435) toxicities with 
Pa values that are somewhat higher than those predicted 
for its cyclic hemiacetalic form. A very similar pattern 
of toxic and adverse effects is predicted for the open 
dialdehydic form of DOA, including skin irritation (Pa 
= 0.954) and eye irritation (Pa = 0.823) effects as well 
as embryotoxic (Pa = 0.456), and teratogenic (Pa = 
0.429) activities.  
 
Contributions of particular atoms to the anti-
aging/anti-cancer activities of EVOO oleuropeins 
 
To preliminarily elucidate hypothesis-generating 
structural requirements of gerosuppressant oleuropeins, 
we assessed how the naturally occurring chemical 
structures of OA and DOA (i.e., the hemiacetalic closed 
forms versus dialdehydic open forms) impact some anti-
aging/anti-cancer-related effects predicted with 
probabilities of Pa > 0.500 by PASS (i.e., among the top 
10 pharmacological effects predicted for each 
polyphenol isomeric form). Some of the pharma-






























previously reported anti-aging and anti-cancer effects of 
OA and DOA (i.e., anti-oxidant, anti-inflammatory, and 
anti-neoplastic effects) are exclusively restricted to the 
hemiacetalic cyclic forms of OA and DOA (Fig. 4). The 
apoptosis agonist effect is predicted to occur with a 
notably higher probability in the cyclic hemiacetalic 
form of DOA (Pa = 0.610) than in the cyclic 
hemiacetalic form of OA (Pa = 0.419). Fig. 4 allows 
assessment of the impact of particular atoms on 
particular activities of the oleuropein isomers (green 
indicates a “positive impact”, blue a “neutral impact”, 
and red a “negative impact”). As green-colored atoms 
reflect a positive impact on a given activity while the 
red-colored atoms reflect a negative impact on the same 
activity, it should be noted that the chemopreventive 
mechanisms of action that are significantly predicted for 
the open dialdehydic forms of OA and DOA, but not for 
their cyclic hemiacetalic isomers mostly involve all of 
the atoms involved in the polyphenolic structure of 
DOA. Remarkably, as observed for many drugs with 
potential antineoplastic and chemopreventive 
properties, including curcumin and resveratrol [44-50], 
the open dialdehydic forms of OA and DOA are 


































and apoptosis agonist activities with a Pa > 0.4 obtained  for  the hemiacetalic closed  forms of OA
and DOA that are not predicted (Pa < 0.2) for the dialdehydic open forms of OA and DOA.  
  
www.impactaging.com                   737                                 AGING, September 2014, Vol. 6 No.9
DISCUSSION 
 
Aging is associated with common conditions, including 
cancer, diabetes, cardiovascular disease, and 
Alzheimer’s disease. A multi-targeted pharmacological 
approach necessary for addressing a complex 
multifaceted disease such as aging might take advantage 
of pleiotropic natural polyphenols affecting a wide 
range of biological processes. We recently postulated 
that the secoiridoids OA and DOA, two complex 
polyphenols present in health-promoting EVOO, might 
constitute a new family of plant-produced 
gerosuppressant agents [29, 32]. This paper describes, 
for the first time, the analysis of BAS for OA and DOA 
using PASS software. 
 
The PASS algorithm is based on the concept of the 
BAS, which should be viewed as an intrinsic property 
of a compound. The BAS reflects all of the various 
biological activities that arise from the interactions of a 
compound with biological entities. Because in PASS, 
the biological activity spectrum represents a theoretical 
estimate for the general biological potential of the 
compound under study, this definition differs 
significantly from some other definitions of a 
“biological activity profile” or “biological activity 
spectrum” that are commonly published in the literature. 
PASS can then simultaneously predict pharmacological 
effects, mechanisms of action, mutagenicities, 
carcinogenicities, teratogenicities, and embryotoxicities 
based exclusively on the structural formula of a 
substance [33-43]. Using Pharmaexpert, a tool that 
analyzes the BAS of substances predicted by PASS 
based on a knowledgebase including thousands of 
“mechanism-effect(s)” and “effect-mechanism(s)” 
relationships, we have elucidated hypothesis-generating 
pharmacological effects, mechanisms of action, and 
targets that might underlie the anti-aging/anti-cancer 
activities of EVOO oleuropeins for the first time.  
 
The results of the application of PASS to EVOO 
oleuropeins strongly support the notion that plant-
derived dietary polyphenols may improve some disease 
states and promote health by operating as pleiotropic 
molecules that are capable of interacting with multiple 
molecular targets involved in aging and cancer-related 
processes, such as oxidation, inflammation, cholesterol 
and lipid synthesis, and immunosuppression. Although 
forthcoming studies should mechanistically confirm the 
predicted ability of the EVOO oleuropein DOA to exert 
anti-inflammatory, antihypercholesterolemic, and/or 
hepatoprotectant effects as part of the anti-aging and/or 
anti-cancer responses of DOA in in vivo models, we 
note that several studies have confirmed preventive 
effects of OA in experimental models of inflammation, 
inflammatory angiogenesis, and arthritis, in addition to 
hepatoprotective effects of OA in mice, 
chemopreventive effects in endothelial dysfunction-
associated vascular diseases, and cardioprotective and 
neuroprotective effects [51-66].  
 
Importantly, the results of our application of PASS to 
the EVOO oleuropeins OA and DOA, which exhibit 
two naturally occurring isomeric structures, strongly 
suggest that a different biological activity spectrum can 
be expected from hemiacetalic versus dialdehydic 
forms. In aqueous or physiological media, it should be 
assumed that both types of compounds exist in an 
equilibrium mixture consisting of a hemiacetal (i.e., the 
cyclic form) and a dialdehyde isomer (i.e., the open 
form). Although this equilibrium could be shifted in 
practice, for instance, by the preferential interaction of 
one of the isomers with a target protein, the dialdehyde 
form appears to be more conformationally free and 
adaptable to interact with a suitable target. It should be 
noted that the presence of the methoxycarbonyl 
constituent in OA clearly favors the cyclic hemiacetalic 
form due to the conjugation of the ester group with the 
internal double bond. In sharp contrast, a much greater 
ratio favoring the open dialdehydic form should be 
expected for DOA. Accordingly, the reported 1H-NMR 
of DOA shows that the dialdehyde form largely 
predominates [67-69]. In this regard, it is intriguing that 
application of PASS software to the isomeric forms of 
OA and DOA exclusively predicted (at least with high 
Pa values) chemopreventive activity for the open 
dialdehydic forms of OA, and more significantly, DOA. 
Chemopreventive agents derived from edible plants 
have been a part of the daily intake of many humans 
and animals since ancient times. There are multiple 
lines of compelling evidence from epidemiological, 
clinical, and laboratory studies that these dietary 
constituents are associated with a reduction of cancer 
risk [70-72]. It is reasonable to suggest that the 
gerosuppressant secoiridoids OA and DOA found in 
EVOO might be added to the list of plant-derived 
chemopreventive agents, not only based on their 
predicted antineoplastic effects, which have been 
unambiguously confirmed by our group in in vitro 
studies with cultured cancer cells, but also based on 
their predicted toxicities. Archetypal anti-aging/anti-
cancer polyphenols, such as curcumin and resveratrol, 
have been shown to operate as “double-edged swords”, 
such that in vitro experiments reveal carcinogenic and 
pro-oxidant effects, in addition to anticancer and 
antioxidant effects. Accordingly, these polyphenols 
have been shown to exert embryotoxic and teratogenic 
effects using zebrafish embryos as disease models [44-
50]. The PASS predictions obtained in the present study 
similarly predict carcinogenic, embryotoxic, and 
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teratogenic effects for the dialdehydic forms of OA and 
DOA. Under the assumption that inhibition of 
developmentally regulated genes in vitro might also 
predict developmental toxicity under in vivo conditions 
[72], experiments are currently underway in our 
laboratory to examine the effect of the chemopreventive 
EVOO secoiridoid DOA on both the induction and 
differentiation of mouse induced pluripotent stem cells 
(iPSCs), as an in vitro model of embryotoxicity and the 
tumor-initiation properties of cancer stem cells.  
 
We have recently postulated that the secoiridoids OA 
and DOA, two complex polyphenols present in health-
promoting EVOO, might constitute a new family of 
plant-produced gerosuppressant agents [29, 32]. We 
demonstrated that the anticancer activity of EVOO 
phenolic extracts that were highly enriched in the 
secoiridoids OA and DOA was intriguingly related to 
the activation of anti-aging/cellular stress-like gene 
signatures (e.g., associated with endoplasmic reticulum 
stress, the unfolded protein response, spermidine and 
polyamine metabolism, AMPK activation, suppression 
of crucial genes involved in the Warburg effect and the 
self-renewal capacity of “immortal” cancer stem cells), 
while the same OA- and DOA-enriched phenolic 
extracts significantly prevented age-related changes in 
cell size, morphological heterogeneity, and senescence-
associated β-galactosidase staining of normal diploid 
human fibroblasts at the end of their proliferative 
lifespans [29]. Because the exploration of putative 
therapeutic mechanisms using conventional wet 
laboratory experiments to obtain a better understanding 
of the ultimate pharmacological behavior of these 
polyphenolic gerosuppressants was expected to be 
tedious, time consuming, and expensive, we were 
encouraged to develop in silico techniques. The results 
of the present study confirm that PASS software is 
extremely useful for the elucidation of unknown 
therapeutic mechanisms in plant-based drug discovery 
and, more importantly, reveals hypothesis-generating 
pharmacological effects, mechanisms of action, and 
targets that likely underlie the anti-aging/anti-cancer 
activities of complex polyphenols that are naturally 
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